Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 361

1.

Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial.

Younossi ZM, Ratziu V, Loomba R, Rinella M, Anstee QM, Goodman Z, Bedossa P, Geier A, Beckebaum S, Newsome PN, Sheridan D, Sheikh MY, Trotter J, Knapple W, Lawitz E, Abdelmalek MF, Kowdley KV, Montano-Loza AJ, Boursier J, Mathurin P, Bugianesi E, Mazzella G, Olveira A, Cortez-Pinto H, Graupera I, Orr D, Gluud LL, Dufour JF, Shapiro D, Campagna J, Zaru L, MacConell L, Shringarpure R, Harrison S, Sanyal AJ; REGENERATE Study Investigators.

Lancet. 2019 Dec 5. pii: S0140-6736(19)33041-7. doi: 10.1016/S0140-6736(19)33041-7. [Epub ahead of print]

PMID:
31813633
2.

Troponin elevation in the setting of exercise-induced rhabdomyolysis in an athletic teenager.

Rausa J, Shetty I, Loomba RS.

Cardiol Young. 2019 Dec 3:1-4. doi: 10.1017/S1047951119002518. [Epub ahead of print]

PMID:
31791434
3.

The Role of Noninvasive Tests for Differentiating NASH From NAFL and Diagnosing Advanced Fibrosis Among Patients With NAFLD.

Balakrishnan M, Loomba R.

J Clin Gastroenterol. 2019 Nov 26. doi: 10.1097/MCG.0000000000001284. [Epub ahead of print]

PMID:
31789757
4.

A randomized, double-blind, multicenter, phase 2b study to evaluate the safety and efficacy of a combination of tropifexor and cenicriviroc in patients with nonalcoholic steatohepatitis and liver fibrosis: Study design of the TANDEM trial.

Pedrosa M, Seyedkazemi S, Francque S, Sanyal A, Rinella M, Charlton M, Loomba R, Ratziu V, Kochuparampil J, Fischer L, Vaidyanathan S, Anstee QM.

Contemp Clin Trials. 2019 Nov 13;88:105889. doi: 10.1016/j.cct.2019.105889. [Epub ahead of print]

PMID:
31731005
5.

The Progress and Significance of QRS Duration by Electrocardiography in Hypoplastic Left Heart Syndrome.

Karikari Y, Abdulkarim M, Li Y, Loomba RS, Zimmerman F, Husayni T.

Pediatr Cardiol. 2019 Nov 13. doi: 10.1007/s00246-019-02237-6. [Epub ahead of print]

PMID:
31722042
6.

Acute Effects of Hypoxic Gas Admixtures on Pulmonary Blood Flow and Regional Oxygenation in Children Awaiting Norwood Palliation.

Thomas L, Flores S, Wong J, Loomba R.

Cureus. 2019 Sep 18;11(9):e5693. doi: 10.7759/cureus.5693.

7.

Editorial: evolving histological assessment of NASH. Authors' reply.

Pai RK, Feagan BG, Parker CE, Jairath V, Loomba R.

Aliment Pharmacol Ther. 2019 Dec;50(11-12):1245-1246. doi: 10.1111/apt.15570. No abstract available.

PMID:
31709613
8.

A Unique Case of Middle Aorta Syndrome With a "Corkscrew" Descending Aorta.

Abdulkarim M, Karikari Y, Loomba RS, Anderson RH, Vricella L, El-Zein C.

World J Pediatr Congenit Heart Surg. 2019 Nov;10(6):799-800. doi: 10.1177/2150135119873854.

PMID:
31701825
9.

Insulin sensitizer MSDC-0602K in non-alcoholic steatohepatitis: A randomized, double-blind, placebo-controlled phase IIb study.

Harrison SA, Alkhouri N, Davison BA, Sanyal A, Edwards C, Colca JR, Lee BH, Loomba R, Cusi K, Kolterman O, Cotter G, Dittrich HC.

J Hepatol. 2019 Nov 4. pii: S0168-8278(19)30650-6. doi: 10.1016/j.jhep.2019.10.023. [Epub ahead of print]

PMID:
31697972
10.

Cost-Effectiveness Analysis of Screening for Hepatitis B Virus Infection in Patients with Solid Tumors before Initiating Chemotherapy.

Konijeti GG, Grandhe S, Konerman M, Lane J, Shrime M, Singh S, Loomba R.

Clin Gastroenterol Hepatol. 2019 Oct 31. pii: S1542-3565(19)31241-8. doi: 10.1016/j.cgh.2019.10.039. [Epub ahead of print]

PMID:
31678602
11.

Impact of obeticholic acid on the lipoprotein profile in patients with non-alcoholic steatohepatitis.

Siddiqui MS, Van Natta ML, Connelly MA, Vuppalanchi R, Neuschwander-Tetri BA, Tonascia J, Guy C, Loomba R, Dasarathy S, Wattacheril J, Chalasani N, Sanyal AJ; NASH CRN.

J Hepatol. 2019 Oct 18. pii: S0168-8278(19)30607-5. doi: 10.1016/j.jhep.2019.10.006. [Epub ahead of print]

12.

Letter: probiotics? Yes, but which ones? Authors' reply.

Jayakumar S, Loomba R.

Aliment Pharmacol Ther. 2019 Oct;50(8):968. doi: 10.1111/apt.15469. No abstract available.

PMID:
31591781
13.

Association of Histologic Disease Activity With Progression of Nonalcoholic Fatty Liver Disease.

Kleiner DE, Brunt EM, Wilson LA, Behling C, Guy C, Contos M, Cummings O, Yeh M, Gill R, Chalasani N, Neuschwander-Tetri BA, Diehl AM, Dasarathy S, Terrault N, Kowdley K, Loomba R, Belt P, Tonascia J, Lavine JE, Sanyal AJ; Nonalcoholic Steatohepatitis Clinical Research Network.

JAMA Netw Open. 2019 Oct 2;2(10):e1912565. doi: 10.1001/jamanetworkopen.2019.12565.

14.

Standardising the interpretation of liver biopsies in non-alcoholic fatty liver disease clinical trials.

Pai RK, Kleiner DE, Hart J, Adeyi OA, Clouston AD, Behling CA, Jain D, Kakar S, Brahmania M, Burgart L, Batts KP, Valasek MA, Torbenson MS, Guindi M, Wang HL, Ajmera V, Adams LA, Parker CE, Feagan BG, Loomba R, Jairath V.

Aliment Pharmacol Ther. 2019 Nov;50(10):1100-1111. doi: 10.1111/apt.15503. Epub 2019 Oct 3.

PMID:
31583739
15.

Clinical utility of an increase in magnetic resonance elastography in predicting fibrosis progression in NAFLD.

Ajmera VH, Liu A, Singh S, Yachoa G, Ramey M, Bhargava M, Zamani A, Lopez S, Mangla N, Bettencourt R, Rizo E, Valasek M, Behling C, Richards L, Sirlin C, Loomba R.

Hepatology. 2019 Sep 25. doi: 10.1002/hep.30974. [Epub ahead of print]

PMID:
31556124
16.

The 20% Rule of NASH Progression: The Natural History of Advanced Fibrosis and Cirrhosis Caused by NASH.

Loomba R, Adams LA.

Hepatology. 2019 Dec;70(6):1885-1888. doi: 10.1002/hep.30946. No abstract available.

PMID:
31520407
17.

Histologic Findings of Advanced Fibrosis and Cirrhosis in Patients With Nonalcoholic Fatty Liver Disease Who Have Normal Aminotransferase Levels.

Gawrieh S, Wilson LA, Cummings OW, Clark JM, Loomba R, Hameed B, Abdelmalek MF, Dasarathy S, Neuschwander-Tetri BA, Kowdley K, Kleiner D, Doo E, Tonascia J, Sanyal A, Chalasani N; and the NASH Clinical Research Network.

Am J Gastroenterol. 2019 Oct;114(10):1626-1635. doi: 10.14309/ajg.0000000000000388.

PMID:
31517638
18.

Modified Single-Patch versus Two-Patch Repair for Atrioventricular Septal Defect: A Systematic Review and Meta-Analysis.

Loomba RS, Flores S, Villarreal EG, Bronicki RA, Anderson RH.

World J Pediatr Congenit Heart Surg. 2019 Sep;10(5):616-623. doi: 10.1177/2150135119859882.

PMID:
31496417
19.

Gut Microbiome-Based Metagenomic Signature for Non-invasive Detection of Advanced Fibrosis in Human Nonalcoholic Fatty Liver Disease.

Loomba R, Seguritan V, Li W, Long T, Klitgord N, Bhatt A, Dulai PS, Caussy C, Bettencourt R, Highlander SK, Jones MB, Sirlin CB, Schnabl B, Brinkac L, Schork N, Chen CH, Brenner DA, Biggs W, Yooseph S, Venter JC, Nelson KE.

Cell Metab. 2019 Sep 3;30(3):607. doi: 10.1016/j.cmet.2019.08.002. No abstract available.

PMID:
31484056
20.

Use of vasoactive agents in postoperative pediatric cardiac patients: Insights from a national database.

Loomba RS, Flores S.

Congenit Heart Dis. 2019 Aug 27. doi: 10.1111/chd.12837. [Epub ahead of print]

PMID:
31454161

Supplemental Content

Loading ...
Support Center